

**In the Figures:**

Please replace originally-filed Figures 1B-1D with the replacement Figures 1B-1D, attached herewith. Annotated marked up drawings of original Figures 1B-1D are also included for purposes of clarity. The amendments to the Figures are explained in the remarks section.

**Sequence Listing:**

Please incorporate the sequence listing into the application. The sequence listing is submitted herewith on CD in duplicate, in lieu of the paper copy, in compliance with 37 CFR §§ 1.821(c) and 1.52 and on CD in compliance with 37 CFR § 1.821(e) (CRF copy). The sequence listing does not contain new matter.

As required by 37 CFR § 1.821(f): the copy of the sequence listing on CD (in lieu of paper copy) is the same as the CRF copy of the sequence listing.

## REMARKS

### Specification

The specification is amended to incorporate by reference, the CD copies of the sequence listing submitted under 37 C.F.R. §§ 1.821(c) and 1.52(e). No new matter is added by this amendment.

### Sequence Listing

The sequence listing, submitted in duplicate on CD, in lieu of a paper copy, and on CD (CRF copy) in compliance with 37 C.F.R. §§ 1.821(c),(e) corresponds with the amendments made to Figures 1B-1D. The Sequence Listing has been generated from the specification and Figures and does not constitute new matter. The Sequence Listing has been prepared using PatentIn 3.3 and checked with Checker 4.2. No error has been found.

### Figures

Replacement Figures 1B-1D are amended to include the appropriate unique and non-redundant SEQ ID NOs., in compliance with 37 CFR §1.821-1.825. The amendments are indicated in red pen on the "annotated marked up drawing" sheets, attached herewith. These amendments do not constitute new matter.


### Oath/Declaration

Applicants submit the Oath/Declaration for the application, executed by each inventor (37 C.F.R. §1.63). A check for the surcharge fee (\$65.00) associated with late filing of the oath/declaration is included.


Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff LLP**

Date: October 4, 2004


By: \_\_\_\_\_

  
Christopher P. Singer  
Reg. No. 48,701

**Figure 1B: Example of a duplex forming oligonucleotide sequence that utilizes a palindrome or repeat sequence**



**Figure 1C: Example of a duplex forming oligonucleotide sequence that utilizes a palindrome or repeat sequence, self assembly**



**Figure 1D: Example of a duplex forming oligonucleotide sequence that utilizes a palindrome or repeat sequence, self assembly and inhibition of Target Sequence Expression**

